TY - JOUR
T1 - Neuregulin in neuron/glial interactions in the central nervous system
T2 - GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination
AU - Marchionni, Mark A.
AU - Cannella, Barbara
AU - Hoban, Carolyn
AU - Gao, Yan Ling
AU - Garcia-Arenas, Renee
AU - Lawson, Deborah
AU - Happel, Elizebeth
AU - Noel, Florence
AU - Tofilon, Philip
AU - Gwynne, David
AU - Raine, Cedric S.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Glial growth factor 2 (GGF2) is a neuronal signal that promotes the proliferation and survival of the oligodendrocyte, the myelinating cell of the central nervous system (CNS). This study has focused on recombinant human GGF2 (rhGGF2) and it's potential to affect clinical recovery and repair to damaged myelin in chronic relapsing experimental autoimmune encephalomyelitis (EAE) in the mouse, a major animal model for the human demyelinating disease, multiple sclerosis (MS). Mice, with EAE were treated with rhGGF2 during both the acute and relapsing phases, and GGF2 treatment led to delayed signs, decreased severity and resulted in statistically significant reductions in relapse rate. Further, rhGGF2-treated groups displayed CNS lesions with more remyelination than in controls. This correlated with increased expression of myelin basic protein exon 2, a marker for remyelination, and with an increase of the regulatory cytokine, IL-10. Thus, a beneficial effect of a neurotrophic growth factor has been demonstrated upon the clinical, pathologic and molecular manifestations of autoimmune demyelination, an effect that was associated with increased expression of a Th2 cytokine, rhGGF2 treatment may represent a novel approach to the treatment of MS (Cannella et al., 1998).
AB - Glial growth factor 2 (GGF2) is a neuronal signal that promotes the proliferation and survival of the oligodendrocyte, the myelinating cell of the central nervous system (CNS). This study has focused on recombinant human GGF2 (rhGGF2) and it's potential to affect clinical recovery and repair to damaged myelin in chronic relapsing experimental autoimmune encephalomyelitis (EAE) in the mouse, a major animal model for the human demyelinating disease, multiple sclerosis (MS). Mice, with EAE were treated with rhGGF2 during both the acute and relapsing phases, and GGF2 treatment led to delayed signs, decreased severity and resulted in statistically significant reductions in relapse rate. Further, rhGGF2-treated groups displayed CNS lesions with more remyelination than in controls. This correlated with increased expression of myelin basic protein exon 2, a marker for remyelination, and with an increase of the regulatory cytokine, IL-10. Thus, a beneficial effect of a neurotrophic growth factor has been demonstrated upon the clinical, pathologic and molecular manifestations of autoimmune demyelination, an effect that was associated with increased expression of a Th2 cytokine, rhGGF2 treatment may represent a novel approach to the treatment of MS (Cannella et al., 1998).
UR - http://www.scopus.com/inward/record.url?scp=0034466119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034466119&partnerID=8YFLogxK
M3 - Article
C2 - 10635037
AN - SCOPUS:0034466119
SN - 0065-2598
VL - 468
SP - 283
EP - 295
JO - Advances in experimental medicine and biology
JF - Advances in experimental medicine and biology
ER -